The Institute of Radioelements (IRE) has commissioned the Louvain-la-Neuve-based company IBA to install a particle accelerator for the production of radioisotopes for the diagnosis of numerous cancer types such as neuroendocrine tumors and prostate cancer IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of solutions for the diagnosis and treatment of cancer, and IRE, the world leader in the production of radioisotopes for diagnostic and therapeutic applications in the field of nuclear medicine, announce today that they have signed a contract for the installation of a cyclotron with an energy of 30 MeV (mega electron volt) on an IRE site. Commissioning is scheduled for 2023. Belgium is internationally…